Summer 2022 Hybrid Symposium

"Targeted Therapies - Focus on the Future"

Thursday, July 21, 2022
8 am - 12 noon CDT

Program Book
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formerly known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

**NEW TERM** An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

<table>
<thead>
<tr>
<th>NAME</th>
<th>Individual's Role(s) in Activity</th>
<th>Nothing To Disclose</th>
<th>DISCLOSURE &lt;company &amp; role&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Planning Disclosures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roisin O’Cearbhaill, MD</td>
<td>Program Chair</td>
<td>AbbVie; Atara Biotherapeutics; Bayer; Genentech; GSK; Kite Pharma; Ludwig Cancer Inst; Marker Therapeutics; Merck; Regeneron Pharmaceuticals; Seagen; Sellas Therapeutics; Syndax Pharmaceuticals; TCR2 Therapeutics: Grant/Contract Bayer; Carina Biotech; Fresenius Kabi USA, LLC; GSK; Immunogen; Regeneron Pharmaceuticals; Seagen Inc: Consultant</td>
<td></td>
</tr>
<tr>
<td>Katherine Fuh, MD, PhD</td>
<td>Co-Chair</td>
<td>Genentech; Myriad Genetic Laboratories, Inc: Consultant</td>
<td></td>
</tr>
<tr>
<td><strong>Speaker Disclosures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rebecca Arend, MD</td>
<td>Speaker</td>
<td>Caris Life Sciences: Consultant AstraZeneca; Clovis Oncology; GSK, Leap Therapeutics; Merck; Seagen; Sutro Biopharma; VBL Therapeutics: Other</td>
<td></td>
</tr>
<tr>
<td>Emeline Aviki, MD</td>
<td>Speaker</td>
<td>Eli Lilly and Company: Grant/Contract Merck: Consultant</td>
<td></td>
</tr>
<tr>
<td>Emma Barber, MD</td>
<td>Speaker</td>
<td>Aravive; AstraZeneca; GSK, Seattle Genetics; Roche; Merck: Contracted Research with Institution</td>
<td></td>
</tr>
<tr>
<td>Stephanie Blank, MD</td>
<td>Speaker</td>
<td>AstraZeneca Canada; GSK: Other F. Hoffmann-La Roche: Grant/Contract</td>
<td></td>
</tr>
<tr>
<td>Yvette Drew, MD, PhD</td>
<td>Speaker</td>
<td>Aileron Therapeutics; Amgen; Aprea Therapeutics; Astex Therapeutics; Bayer HealthCare Pharmaceuticals Inc.; Bellicum Pharmaceuticals; BOLT Therapeutics; Compugen Ltd; Immunocore LTD; Immunomedics, Inc.; Mereo BioPharma S Inc; NCI; PMV Pharma; Sanofi; Seagen Inc.; TRACON Pharmaceuticals Inc; Triumvira; Unum Therapeutics: Grant / Contract Catamaran Bio: Consultant Mersana: Other</td>
<td></td>
</tr>
<tr>
<td>Ecaterina Dumbrava, MD</td>
<td>Speaker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Britt Erickson, MD</td>
<td>Speaker</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Disclosures</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Katherine Fuh, MD, PhD</td>
<td>Speaker</td>
<td>Genentech; Myriad Genetic Laboratories, Inc; Consultant</td>
<td></td>
</tr>
<tr>
<td>Marina Garassino, MD</td>
<td>Speaker</td>
<td>AstraZeneca; MSD International GmbH; BMS; Boehringer Ingelheim Italia S.p.A; Celgene; Eli Lilly; Ignyta; Incyte; Invata; MedImmune; Novartis; Pfizer; Roche; Takeda; Seattle Genetics; Mirati; Daiichi Sankyo; Regeneron; Merck; Ose Immuno Therapeutics: Personal Financial Interests Eli Lilly; MSD; Pfizer (MISP); AstraZeneca; MSD International GmbH; BMS; Boehringer Ingelheim Italia S.p.A; Celgene; Eli Lilly; Ignyta; Incyte; MedImmune; Novartis; Pfizer; Roche; Takeda; Tiziana; Foundation Medicine; GSK; Spectrum pharmaceuticals; Institutional financial interests AIRC; Aifa; Italian Moh; TRANSCAN; research fundings: Other</td>
<td></td>
</tr>
<tr>
<td>Gottfried Konecny, MD, PhD</td>
<td>Speaker</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Mario Lacouture, MD</td>
<td>Speaker</td>
<td>F. Hoffmann-La Roche; <a href="https://openpaymentsdata.cms.gov/physician/302987">https://openpaymentsdata.cms.gov/physician/302987</a>; Incyte Corporation ; Janssen Biotech; kinnate; laroche posay; repare; Seagen Inc.; trifecta: Consultant AstraZeneca; Columbia; lutris; nanology; Novartis; Novocure Inc.; oql: Grant/Contract oncoderm labs: Other Business Ownership</td>
<td></td>
</tr>
<tr>
<td>Haider Mahdi, MD</td>
<td>Speaker</td>
<td>Puma Biotechnology: Grant/Contract</td>
<td></td>
</tr>
<tr>
<td>Jyoti Mayadev, MD</td>
<td>Speaker</td>
<td>AstraZeneca; Merck; primmune; Varian Medical Systems: Consultant</td>
<td></td>
</tr>
<tr>
<td>Roisin O’Cearbhaill, MD</td>
<td>Speaker</td>
<td>AbbVie; Atara Biotherapeutics; Bayer; Genentech; GSK; Kite Pharma; Ludwig Cancer Inst; Marker Therapeutics; Merck; Regeneron Pharmaceuticals; Seagen; Sellas Therapeutics; Syndax Pharmaceuticals; TCR2 Therapeutics: Grant/Contract Bayer; Carina Biotech; Fresenius Kabi USA, LLC; GSK; Immunogen; Regeneron Pharmaceuticals; Seagen Inc: Consultant Hitech Health: Travel</td>
<td></td>
</tr>
<tr>
<td>Yeku Oladapo, MD</td>
<td>Speaker</td>
<td>GIMV NV; TigaTx Inc: Consultant Cellfree Therapeutics ; HC Bioscience: Other</td>
<td></td>
</tr>
<tr>
<td>Deb Richardson, MD</td>
<td>Speaker</td>
<td>AstraZeneca; Deciphera; Genentech USA, Inc; GSK; Immunogen; Mersana: Consultant</td>
<td></td>
</tr>
</tbody>
</table>

Symposium - July 2022
Accreditation Statement
The GOG Foundation, Inc. is accredited by the ACCME to provide Continuing Education for physicians.

AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The GOG Foundation Inc. Continuing Education (CME) Program Mission Statement
The purpose of The GOG Foundation, Inc. CE program is to provide and promote an infrastructure dedicated to enhancing the knowledge base of meeting participants and guests centered on the development, execution, analysis and application of GOG-supported clinical trials. To that end, the CME Program engages in these discussions member researchers and invited clinicians committed to reducing the risk and improving outcomes for women at risk for or afflicted with a gynecologic malignancy.

Disclosure Declaration
In compliance with ACCME regulations, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. All reported conflicts are managed by a designated official to ensure a bias-free presentation. Please see the complete disclosure list included with this program.

How do I collect CME Certificates?
After you attend your session(s), click the "Survey" icon on the right side of the Attendee Hub or in the Meeting APP: (seen here)

Survey

This link will direct you to all the session evaluations/surveys available to you for completion.

You can also click the "Survey" icon located at the bottom of your Attendee Hub Home Page.

CMEs: Upon completion of your evaluations/surveys, certificates will be sent to the email you used to register.

If you have issues accessing your certificate or questions about CME, please contact: cmeinfo@gog.org.
Program Description

This Summer 2022 Hybrid Educational Symposium is being held in-person and virtually with noted Oncologists and Scientists serving as speakers and moderators.

The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, Patient Advocates and others engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, Physician Assistants, and other interested Allied Health professionals.

The speakers will focus their presentations on:

- Appropriate settings to utilize currently available targeted therapies
- Current clinical trials of novel targeted therapies
- Promising future approaches in targeted therapies.

Learning Objectives

Following this activity, participants will be better able to:

- Recognize appropriate settings to utilize currently available targeted therapies
- Outline future clinical trial opportunities for patients
- Distinguish current and promising future approaches to targeted therapies
- Manage toxicity related to targeted therapies

Program Chair: Roisin O’Cearbhail, MD - Co-Chair: Katherine Fuh, MD, PhD

Presentation agenda on next page
## Summer 2022 Symposium - “Targeted Therapies – Focus on the Future”
Thurs, July 21, 2022 – 8 am to 12 pm – CDT - NRG Oncology Summer 2022 Mtg- Chicago, Illinois – (In-person/Virtual)

### Presentation Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Welcome/Opening Remarks</td>
<td>Katherine Fuh, MD, PHD</td>
</tr>
<tr>
<td>8:05 am</td>
<td>Session 1 – Focus on other Solid Tumors</td>
<td>Moderators: Rebecca Arend, MD and Britt Erickson, MD</td>
</tr>
<tr>
<td>8:05-8:25</td>
<td>Lessons from Lung Cancer</td>
<td>Marina Garassino, MD</td>
</tr>
<tr>
<td>8:25-8:45</td>
<td>Targeted Therapies with Radiation in Locally Advanced Cervical Cancer and Solid Tumors</td>
<td>Jyoti Mayadev, MD</td>
</tr>
<tr>
<td>8:45-9:05</td>
<td>HER2 Targeting Agents</td>
<td>Ecaterina Dumbrava, MD</td>
</tr>
<tr>
<td>9:05-9:15</td>
<td>Panel Q &amp; A</td>
<td>Panel</td>
</tr>
<tr>
<td>9:15-9:25</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>9:25</td>
<td>Session 2 – Focus on the Future</td>
<td>Moderators: Deb Richardson, MD and Haider Mahdi, MD</td>
</tr>
<tr>
<td>9:25-9:45</td>
<td>Targeting the DNA Damage Response and Repair</td>
<td>Yvette Drew, MD, PhD</td>
</tr>
<tr>
<td>9:45-10:05</td>
<td>Focus on Eye Toxicities</td>
<td>Gottfried Konecny, MD, PhD</td>
</tr>
<tr>
<td>10:05-10:25</td>
<td>Bispecifics/Antibody Drug Conjugates</td>
<td>Yeku Oladapo, MD, PhD</td>
</tr>
<tr>
<td>10:25-10:35</td>
<td>Panel Q &amp; A</td>
<td>Panel</td>
</tr>
<tr>
<td>10:35-10:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Session 3 – Focus on the Patient</td>
<td>Moderators: Stephanie Blank, MD and Emma Barber, MD</td>
</tr>
<tr>
<td>10:45-11:05</td>
<td>Targeting Financial Toxicity</td>
<td>Emeline Aviki, MD</td>
</tr>
<tr>
<td>11:05-11:35</td>
<td>Targeting Skin Toxicity</td>
<td>Mario Lacouture, MD</td>
</tr>
<tr>
<td>11:35-11:45</td>
<td>NCI ComboMATCH</td>
<td>Roisin O’Cearbhaill, MD</td>
</tr>
<tr>
<td>11:45-11:55</td>
<td>Panel Q &amp; A</td>
<td>Panel</td>
</tr>
<tr>
<td>11:55-12:00</td>
<td>Closing Remarks</td>
<td>Roisin O’Cearbhaill, MD</td>
</tr>
</tbody>
</table>

### Evaluation

Participants who complete the educational activity and evaluation will receive a certificate of credit.
Roisin O’Cearbhaill, MD (Symposium Chair)
Associate Professor
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College

Dr. Roisin O’Cearbhaill, MD, is a medical oncologist and Research Director, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center (MSKCC), with a joint faculty appointment at Weill Cornell Medical College. She is the Director, Patient and Family Centered Care Grant initiative and as the Vice-chair, Investigational New Drug/Device committee at MSKCC. Dr. O’Cearbhaill has extensive clinical and research experience in the treatment of gynecological cancers. Her research focuses on the development of novel targeted and immune-based approaches to improve outcomes for women with these cancers. She serves on several international committees and is the Chair, Developmental Therapeutics, NRG Oncology, where she is leading a large phase II/III clinical trial for women with recurrent platinum resistant ovarian cancer. Her research, incorporating cutting-edge technology such as CAR T cells has been highlighted in Science Magazine. She has received numerous awards for her work, including a Conquer Cancer Foundation Career Development Award, Young Investigator Award from the Kaleidoscope of Hope Foundation, Excellence in Research Award from MSKCC and Excellence in teaching award from Weill Cornell Medical College.

Katherine Fuh, MD, PhD (Symposium Co-Chair)
John A. Kerner Chair in Gynecologic Oncology
Associate Professor in Obstetrics and Gynecology
Director of Basic and Translational Research, Gynecologic Oncology
University of California, San Francisco

Dr. Katherine Fuh is a gynecologic oncologist and Director of the Basic and Translational Research for the Division of Gynecologic Oncology at the University of California, San Francisco. She completed her residency in Ob/Gyn at Stanford University, fellowship at the joint UCSF/Stanford program, and Ph.D. in Cancer Biology at Stanford University. She was a scholar in the NIH-funded K12 Reproductive Scientist Development Program (RSDP) at Washington University, St. Louis from 2013-2018 and continued on faculty until 2022. She is currently the John A. Kerner Chair in Gynecologic Oncology and leads a translational lab that focuses on ovarian and uterine cancer in particular targeted therapies and improving sensitivity to treatment within the tumor microenvironment. Her laboratory work has resulted in the development of clinical trials for the treatment of ovarian cancer. She is a member on the NRG Developmental Therapeutics subcommittee, Ovarian Cancer Subcommittee, and the Co-chair of Translational Research of the Uterine Corpus Committee. She is leading a phase III clinical trial for women with recurrent platinum resistant ovarian cancer. She also serves as one of the Deputy Editors for Gynecologic Oncology Reports. She has been the recipient of funding from the Foundation for Women’s Cancer, Ovarian Cancer Research Alliance, Mary Kay Foundation, NCI, American Cancer Society, and the GOG Foundation as a Scholar Investigator.
Rebecca C. Arend, MD, MSPH
University of Alabama at Birmingham
Division of Gynecologic Oncology

Dr. Rebecca Arend is Associate Professor of Gynecologic Oncology at the University of Alabama at Birmingham (UAB) and an Associate Scientist at the UAB O’Neal Comprehensive Cancer Center Experimental Therapeutics Program. She completed her residency at Columbia Presbyterian in New York, NY and completed her fellowship at The University of Alabama at Birmingham. While a fellow at UAB, her review of the Wnt pathway in ovarian cancer became one of the 5 most cited papers in Gynecologic Oncology. After completing her fellowship, Dr. Arend continued her work in the Wnt pathway as a Principal Investigator in her lab within the O’Neal Comprehensive Cancer Center. Her current basic science pursuits include understanding the role of anti-tumor immunity in ovarian cancer through Wnt modulation, metabolism, and epigenetics.

Dr. Arend’s clinical interests include translational research, targeted therapy, chemoresistance, immunotherapy, and personalized medicine. Numerous Gyn Onc fellows, postdoctoral fellows, graduate students, residents, and medical students have trained under her direct mentorship. She is a member of multiple professional societies and committees both regionally and nationally. She has been awarded funding for over five Investigator Initiated trials and has served as both the local and national Principal Investigator on multiple Phase II and III clinical trials. She is the co-chair of UAB’s Gyn and Personalized Medicine Disease Oriented Working Groups, the Chair of the CCC Data Safety Monitoring Committee, and the Chair of UAB Tissue Committee. She is also the Co-Translational Science Chair of NRG’s Ovarian Committee.

Emeline M. Aviki, MD, MBA, FACOG
Assistant Attending, Gynecologic Surgery
Department of Surgery
Memorial Sloan Kettering Cancer Center

Dr. Emeline Aviki, MD, MBA is a Gynecologic Cancer Surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) and Assistant Professor at Weill Cornell Medical College. Dr. Aviki completed her OBGYN residency at Brigham and Women’s and Massachusetts General Hospital and her Gynecologic Oncology fellowship training at MSKCC. Dr. Aviki founded and currently leads the MSKCC Affordability Working group, a team of dedicated clinicians, researchers, and hospital administrators working to address the affordability and financial toxicity issues facing patients with cancer. Dr. Aviki has an Masters in Business Administration and prior to residency she worked as a healthcare strategy consultant. Dr. Aviki’s work focuses on developing system-level interventions to mitigate the effects of financial toxicity in cancer patients which recently led to her being named to the Association for Value-Based Cancer Care’s 40 Under 40 in Cancer list.
Dr. Emma Barber is an Assistant Professor of Gynecologic Oncology at Northwestern University. Dr. Barber received her undergraduate and medical degrees from Yale University, graduating cum laude with honors. She completed her residency at Northwestern University, where she was inducted into the medical honor society Alpha Omega Alpha. She completed both a clinical fellowship and a National Institutes of Health research fellowship at the University of North Carolina at Chapel Hill.

Dr. Barber is a gynecologic oncologist, clinical trialist and health services researcher. Her research focuses on surgical quality and improving the postoperative recovery period so that patients experience fewer complications, recover more quickly and live longer. She has ongoing clinical trials of physical activity prehabilitation among older women with ovarian cancer and surgical window of opportunity studies in women with both endometrial cancer and complex atypical hyperplasia. She has published more than 60 peer-reviewed articles and five book chapters. Her work has been funded by the NICHD, NIA and the NCI. Her research has been featured in prominent peer review publications such as the New England Journal of Medicine, Obstetrics and Gynecology, and Gynecologic Oncology. Her research has won awards from the Society of Gynecologic Oncology and the journal Obstetrics and Gynecology.

Dr. Stephanie V. Blank is Director of Gynecologic Oncology for the Mount Sinai Health System and a Professor in the Department of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai. She is also Associate Director of the Tisch Cancer Institute, Women’s Cancers, and the Director of the Women’s Cancer Program at the Blavatnik Family – Chelsea Medical Center at Mount Sinai. Dr. Blank specializes in treating patients with gynecologic cancers, including ovarian, fallopian tube, primary peritoneal, uterine and cervical cancers, and in caring for those at increased risk of cancer.

Dr. Blank is the President of the Society of Gynecologic Oncology (SGO) and serves on the Executive Committee of the SGO and the Boards of the SGO and Foundation for Women’s Cancer. She is the founder and past chair of the Gender Equity Subcommittee of the Diversity, Inclusion and Health Equity Committee, and is committed to work in this space. She is a member of the Gynecologic Oncology Division of the American Board of Obstetrics and Gynecology and serves on the editorial board of Gynecologic Oncology.

Dr. Blank has conducted extensive research on gynecologic cancers on topics including genetic predisposition to cancer (BRCA 1 and 2, Lynch Syndrome and others), novel treatment approaches, fertility preservation, survivorship and quality of life. She has previously served on the Corpus and Cancer Prevention and Control
Committees of the NRG, and currently is a member of the Ovarian Committee. Additionally, she is a member of the GOG Partners Investigator Council. Dr. Blank has been a principal investigator for multiple clinical trials. She also collaborates with other researchers in the Tisch Cancer Institute on translational research in fields such as immunotherapy and DNA repair. Dr. Blank is broadly published in peer-reviewed journals and text books, and frequently presents at national and international conferences on gynecologic oncology issues. She is the recipient of many honors and awards, including Castle Connolly Top Doctors, Super Doctors, and the Council on Resident Education in Obstetrics and Gynecology Teaching Award, among others.

Dr. Blank earned her medical degree from the University of California, San Diego, School of Medicine. She completed her residency in Obstetrics and Gynecology at the New York Hospital – Cornell Medical Center and a fellowship in Gynecologic Oncology at the University of Pennsylvania Medical Center.

Yvette Drew MD, FRCPC, PhD
Consultant Medical Oncologist and Associate Professor
BC Cancer Vancouver and Faculty of Medicine
University of British Columbia

Dr. Yvette Drew is a Medical Oncologist at BC Cancer Centre Vancouver and Associate Professor at the University of British Columbia, she moved to Canada in May 2021. Dr Drew specializes in the systemic management of gynaecological cancers and early phase clinical trial delivery. She is part of the OVCARE team in Vancouver. Previously Dr Drew worked as a Senior Lecturer and Consultant in Medical Oncology at the Northern Centre for Cancer Care (NCCC) and the Clinical and Translational Research Institute, Newcastle University where she was gynae medical oncology research lead, deputy lead for the Newcastle Experimental Cancer Medicines Centre and undertook basic laboratory gynae focused research within the gynae-oncology translational team.

Dr Drew undertook specialist medical oncology training at the Beatson West of Scotland Cancer Centre, Glasgow and the NCCC. During this time she was awarded a CRUK-funded PhD fellowship investigating the role of PARP inhibitors in Homologous Recombination deficient ovarian cancer. During her PhD she won a Merit award for her research from the American Society of Clinical Oncology (ASCO) and was awarded the Medical Sciences Doctoral Prize (Newcastle university, 2013). She has played a key role in both the pre-clinical and clinical development of the PARP inhibitor rucaparib in ovarian cancer. In the UK she has also led on trials as national CI from first-in-human phase 1 to later phase 3 clinical trials. Research interests include the targeting DNA repair pathways as treatment for gynaecological cancers and PARP inhibitor resistance.

Ecaterina Dumbrava, MD
Assistant Professor
Department of Investigational Cancer Therapeutics
[A Phase I Clinical Trials Program]
The University of Texas MD Anderson Cancer Center

Bio unavailable
Britt K. Erickson, MD  
Assistant Professor, Division of Gynecologic Oncology  
University of Minnesota

Dr. Britt Erickson is a gynecologic oncologist and assistant professor at the University of Minnesota. Her research focuses on chemoprevention and treatment of endometrial cancer and other gynecologic malignancies. She develops and leads clinical trials at the University of Minnesota and Nationally and has recently been awarded the GOG-Foundation Scholar award for her work in late phase endometrial cancer trial development.

Marina Garassino, MD  
Professor of Medicine  
Dept of Medicine, Section Hematology Oncology  
The University of Chicago Medicine

I am currently Professor of Medicine, within the Department of Medicine, Section Hematology Oncology at The University of Chicago. Until February 2021 I was the Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milano, Italy. As a head, I lead the strategy for clinical and translational research in advanced and locally advanced NSCLC, SCLC, mesothelioma and thymic malignancies. As a medical oncologist, I have made research in precision medicine and in immuno-oncology. My main research interests have been mainly development of new drugs and therapeutical strategies and biomarkers. I am the Chair of TYME (Italian network for research of thymic malignancies). I have contributed to over 200 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Annals of Oncology. I had several presentations at international congresses (ASCO, ESMO, ECCO, WCLC, and, AACR). In the last five years, I was able to attract several grants (AIFA, AIRC, and ERA-NET TRANSCAN, Berlucchi, and MISP from pharma companies, etc).

My education includes the degree and further specialization in Medical Oncology at University of Study of Milan (110/110 cum laude) in 1995. I completed my training with a ESMO Clinical fellowship in 2009 at Christie's Hospital in Manchester (UK). I have been a member of EMA SAG (Scientific Advisory Group).

I am serving as ESMO Council and Chair of National Societies. I have been Italian National Representative for 5 years (2011-2017). I’m a member of several ESMO Task forces (Public Policy extended Committee, Press Committee, and Women for Oncology). I’m serving as ASCO Faculty Lung Cancer Track (Annual Meeting 2019). I am founder and honorary president of Women for Oncology Italy.

completed my training with a ESMO Clinical fellowship in 2009 at Christie's Hospital in Manchester (UK). I have been a member of EMA SAG (Scientific Advisory Group).

I am serving as ESMO Council and Chair of National Societies. I have been Italian National Representative for 5 years (2011-2017). I’m a member of several ESMO Task forces (Public Policy extended Committee, Press Committee, and Women for Oncology). I’m serving as ASCO Faculty Lung Cancer Track (Annual Meeting 2019). I am founder and honorary president of Women for Oncology Italy.
Faculty Members – Speakers/Moderators

Gottfried E. Konecny, MD
Professor of Medicine and Ob/Gyn
Gynecologic Medical Oncology Service
Department of Medicine and Ob/Gyn
David Geffen School of Medicine
University of California, Los Angeles

Dr. Gottfried E. Konecny is Professor of Medicine and Obstetrics/Gynecology in the Divisions of Hematology/Oncology and Gynecologic Oncology at the David Geffen School of Medicine at the University of California Los Angeles. He directs the Medical Gynecologic Oncology Program at the University of California Los Angeles and heads the Drug Development Program for Gynecologic Oncology in the Translational Oncology Research Lab at the University of California Los Angeles. He completed his residency training in Obstetrics and Gynecology at the University of Munich, Germany, has completed postdoctoral studies in the laboratory of Dennis J. Slamon at the University of California Los Angeles and completed his Gynecologic Oncology Fellowship training at Mayo Clinic, Rochester, Minnesota. His ongoing research interests include drug discovery and novel therapeutics for ovarian, uterine, and cervical cancer and clinical trial development. He has authored or coauthored over 150 scientific publications, including over 90 peer-reviewed original research articles. He is a member of the European Academy of Arts and Sciences, has served as ASCO program committee chair and co-chair for the NCI Ovarian Cancer Clinical Trials Planning Group and member of the NCCN ovarian cancer consensus panel.

Mario E. Lacouture, MD
Dermatology Service Department of Medicine
Memorial Sloan-Kettering Cancer Center

Dr. Lacouture is a Professor and the director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center in New York City. He conducted his postdoctoral work at Brigham and Women’s Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL. He received his M.D. degree from Javeriana University in Bogota, Colombia, where he grew up. Dr Lacouture began his career in Oncodermatology at The University of Chicago. During his first faculty appointment at Northwestern University, Dr Lacouture received a Zell Scholarship and a Career Development Award from the Dermatology Foundation, and established the first clinical program focused on dermatologic care in cancer patients and survivors. During this time, he initiated the first clinical trials in Oncodermatology, and described mechanisms and treatments on adverse events to novel cancer therapies, published in the Journal of Clinical Oncology and Nature Reviews Cancer. Dr Lacouture founded the Skin Toxicity and the Oncodermatology Study Groups of the Multinational Association of Supportive Care in Cancer, is on the Guidelines Advisory Committee of the American Society of Clinical Oncology, and the Editorial Board of Cancer.Net. In 2012, CancerCare named Dr Lacouture as Physician of the Year for his contributions to the education of people living with cancer, and he has been selected as a Top Doctor in America and New York by Castle Connolly and New York Magazine since 2014. Dr Lacouture has published over 280 articles in peer-reviewed journals and is the author of Dr Lacouture’s Skin Care Guide for People Living With Cancer and Editor of the textbook Dermatologic Principles and Practice in Oncology.
Haider Mahdi, MD  
Assistant Professor and Physician Scientist  
Magee Womens Research Institute  
University of Pittsburgh School of Medicine  
Division of Gynecologic Oncology, Magee  
Womens Hospital, University of Pittsburgh Medical Center  
Cancer Immunology and Immunotherapy Program  
Hillman Cancer Center  

Bio unavailable

Jyoti Mayadev, MD  
Professor, Assistant Vice-Chair Developmental Therapeutics  
Section Chief of Gynecologic Oncology  
Co-Leader of the GYN Oncology Disease Team  
Moores NCI-Designated Comprehensive Cancer Center  

Dr. Jyoti Mayadev is a Professor, Assistant Vice-Chair Developmental Therapeutics, Section Chief of Gynecologic Oncology and serves as Co-Leader of the GYN Oncology Disease Team for the Moores NCI-Designated Comprehensive Cancer Center. She is also Director of Gynecologic Brachytherapy in the Department and oversees all clinical and translational research aspects of image-guided brachytherapy for gynecologic cancers. Dr. Mayadev is a widely recognized national leader in the field of gynecologic radiation therapy and image guided brachytherapy for gynecologic oncology patients. She is Co-Chair of the NRG Oncology Cooperative Group Cervical Cancer committee, and a member of the NRG Oncology phase I/Developmental Therapeutics committee, NRG Early Clinical Trials Oversight cobio page mmittee, NRG Oncology GYN Executive committee, and RT Developmental Therapeutics committee. Furthermore, she is the national principal investigator on phase I clinical trials in cervical cancer exploring the use of immunotherapy in patients with locally advanced cervical cancer. Dr. Mayadev conceived, designed and developed the “Image Guided Brachytherapy Handbook”, and served as the Editor-in-Chief, published by Springer. Dr. Mayadev received the Outstanding Service Award as Co-Chair of the NRG Oncology Developmental Therapeutics/Phase I Committee.
Oladapo Yeku, MD, PhD
Gynecologic Medical Oncology Program
Clinical Assistant in Medicine, Massachusetts General Hospital
Instructor, Harvard Medical School

Dr. Oladapo Yeku is an instructor of Medicine at Harvard Medical School and a Clinical Assistant in Medicine at the Massachusetts General Hospital. Dr. Yeku completed his Medical Oncology fellowship training at Memorial Sloan Kettering Cancer Center (MSKCC). During his fellowship training, Dr. Yeku developed broad expertise in managing a broad variety of gynecologic malignancies, including rare tumors such as clear cell and sarcomas. He is a fellow of the American College of Physicians. He has a Ph.D. in molecular and cellular pharmacology and has received postdoctoral training in immunotherapy and adoptive cellular therapy. While at MSKCC, he conducted preclinical, translational, and clinical research on Chimeric Antigen Receptor T-cells for ovarian cancer. His training and expertise include standard systemic treatment options, immunotherapy, targeted therapy, and clinical trials. As a member of The Henri and Belinda Termeer Center for Targeted Therapies and the Cellular Therapeutic Group, Dr. Yeku is actively involved as a Principal Investigator in early phase drug development and adoptive cellular therapy clinical trials. Dr. Yeku is an associate member of the Vincent Center for Reproductive Biology. His laboratory studies the immunosuppressive tumor microenvironment in Gynecologic Cancers and develops immunotherapeutic approaches to overcome these obstacles.

Debra L. Richardson, MD
Associate Professor, Section Chief of Gynecologic Oncology
Stephenson Cancer Center
University of Oklahoma Health Sciences Center

Debra L. Richardson is Associate Professor of Obstetrics & Gynecology and the Section Chief of Gynecologic Oncology at the Stephenson Cancer Center, University of Oklahoma Health Sciences Center. Dr. Richardson is a clinician, surgeon, and also a clinical trialist. She spends 50% of her time leading phase I clinical trials within the SCC early phase drug development unit. She is a GOG Foundation Scholar, and a member of the GOG Partners Investigator Council. She is very involved in NRG Oncology, and is a member of the Ovarian and Developmental Therapeutics Committees and the Chair of the Early Phase Trial Oversight Committee. She completed residency at the University of Connecticut, Gynecologic Oncology fellowship at The Ohio State University, and was faculty at UT Southwestern for 8 years. She was the PI of GOG 186J, and is currently the national PI of GOG 3048 Uplift and the international PI of GOG 3049 UpNext. Dr. Richardson enjoys doing medical missions- and has completed one to Nigeria and one to the Philippines.
A PDF version of all Final Slide Presentations are available in the Symposium Session Content on the Attendee Hub and Meeting App